Beta Drugs Share Price Soared 17% on Results Day After Q1 FY27 Profit Jumps 41% to Rs 16.49 Crore
- July 21, 2026
- Posted by: Ankit Jaiswal
- Category: News
Beta Drugs share price up 0.43% at Rs 2,450, after soaring 17% on results day. Q1 FY27 PAT Rs 16.49 crore, up 41% YoY. Revenue Rs 125.55 crore, up 25.3% YoY.
The Beta Drugs share price soared over 17 percent on results day after the pharmaceutical company delivered a robust Q1 FY27, with consolidated net profit rising 41 percent year on year to Rs 16.49 crore on the back of 25.3 percent revenue growth to Rs 125.55 crore, extending its gains into trade on 21 July 2026.
Click Here – Get Free Investment Predictions
About Beta Drugs
Beta Drugs manufactures oncology drugs, contract manufacturing products, and consumer healthcare items, with a growing presence in both domestic and export pharmaceutical markets.
The company has been reporting healthy growth across its branded oncology, contract manufacturing, exports, and consumer healthcare businesses, with management reiterating confidence in delivering 20 to 25 percent consolidated growth during FY27.
Beta Drugs’ diversified pharmaceutical portfolio, spanning specialty oncology to consumer healthcare, gives the Beta Drugs share price multiple growth levers that reduce dependence on any single product category or geography.
Beta Drugs Q1 FY27 Results: Key Numbers
| Metric | Q1 FY27 | YoY Change |
|---|---|---|
| Consolidated Revenue | Rs 125.55 crore | Up 25.3% YoY from Rs 100.20 crore |
| Profit Before Tax (PBT) | Rs 22.04 crore | Up nearly 41% YoY |
| Profit After Tax (PAT) | Rs 16.49 crore | Up from Rs 11.70 crore YoY |
| Earnings Per Share (EPS) | Rs 14.78 | Up from Rs 11.59 YoY |
The Beta Drugs share price rally reflects a quarter where profit grew significantly faster than revenue, with 41 percent PAT growth outpacing 25.3 percent revenue growth, indicating the company is not merely selling more but also improving the quality of its earnings through margin expansion.
Healthy growth across branded oncology, contract manufacturing, exports, and consumer healthcare, as highlighted by management, suggests the improvement is broad based rather than concentrated in a single business line, supporting confidence in the sustainability of this quarter’s beat.
Management’s reiteration of its 20 to 25 percent consolidated growth guidance for FY27, alongside reduced finance costs mentioned in company commentary, provides forward looking confirmation that this quarter’s strength is expected to continue rather than being a one-off spike for the Beta Drugs share price.
Consult a SEBI Registered Investment Advisor on Univest
Why Beta Drugs Share Price Is Reacting
The Beta Drugs share price surge of over 17 percent on results day reflects strong market conviction that the company’s growth strategy across multiple pharmaceutical segments is gathering momentum, with margin expansion adding further credibility to the growth story.
Reduced finance costs, cited alongside the operational improvements, suggest the company may be benefiting from a stronger balance sheet position, which can support continued investment in capacity and new product development without excessive debt.
The broad based nature of the growth, spanning oncology, contract manufacturing, exports, and consumer healthcare, likely reassured investors that the Beta Drugs share price rally is grounded in genuine operational strength across the business rather than a single product’s performance.
Outlook for Beta Drugs Share Price
Investors tracking the Beta Drugs share price should watch for continued execution against the company’s stated 20 to 25 percent FY27 growth guidance, since sustaining this pace across multiple quarters would validate the current re-rating.
New product launches and capacity additions in the oncology and contract manufacturing segments will be key catalysts to watch, given these are typically higher margin businesses that could further support profitability.
Export market expansion, particularly for oncology products where India has been gaining global market share, represents an additional growth lever that could extend the Beta Drugs share price momentum beyond the domestic market opportunity.
Download the Univest iOS App or Univest Android App to track Beta Drugs share price live and get instant Q1 result alerts.
Conclusion
Beta Drugs delivered an exceptional Q1 FY27, with profit growing 41 percent to Rs 16.49 crore on 25.3 percent revenue growth, sending the Beta Drugs share price up over 17 percent on results day. Broad based strength across oncology, contract manufacturing, exports, and consumer healthcare, combined with reiterated FY27 growth guidance, supports a constructive outlook. Investors should track execution consistency and consult a SEBI registered adviser before acting on the Beta Drugs share price.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Beta Drugs Q1 FY27 Results
Why did Beta Drugs share price soar on results day?
Ans. The Beta Drugs share price soared over 17 percent after the company reported Q1 FY27 consolidated net profit up 41 percent year on year to Rs 16.49 crore, on 25.3 percent revenue growth to Rs 125.55 crore.
What was Beta Drugs’s Q1 FY27 EPS?
Ans. Beta Drugs reported earnings per share of Rs 14.78 for Q1 FY27, up from Rs 11.59 in Q1 FY26, reflecting the strong profit growth during the quarter.
What products does Beta Drugs manufacture?
Ans. Beta Drugs manufactures oncology drugs, contract manufacturing products, and consumer healthcare items, serving both domestic and export pharmaceutical markets.
What growth guidance has Beta Drugs given for FY27?
Ans. Management reiterated confidence in delivering 20 to 25 percent consolidated growth during FY27, supported by healthy growth across all its business segments in Q1.
Why did profit grow faster than revenue for Beta Drugs?
Ans. Profit grew 41 percent, faster than the 25.3 percent revenue growth, indicating margin expansion, supported by reduced finance costs mentioned alongside the results.
Is Beta Drugs share price a buy after the results?
Ans. This article does not constitute investment advice. While the results were strong, investors should evaluate valuation after the sharp rally and consult a SEBI registered adviser before acting on the Beta Drugs share price.
Where can I track Beta Drugs share price live?
Ans. You can track the Beta Drugs share price live on the Univest app and website, along with quarterly result alerts and research on pharmaceutical stocks.
